Gilead Sciences Reports Phase 2 TROPHY-U-01 Results for Trodelvy in Urothelial Carcinoma

Gilead Sciences today announced results from the Phase 2 TROPHY-U-01 trial evaluating Trodelvy (sacituzumab govitecan) in patients with previously treated metastatic urothelial carcinoma. The trial demonstrated an overall response rate of 27%, with a median duration of response of 7.2 months. These results led to FDA accelerated approval of Trodelvy for urothelial carcinoma.